CD309 / VEGFR-2 / Flk-1 Rabbit Polyclonal Antibody

Specifications

Product Data
Applications	WB
Recommend Dilution	Western blot: 1-5 µg/ml.
Reactivity	Human, Mouse
Host	Rabbit
Clonality	Polyclonal
Immunogen	Peptide of the C-terminal end of native Mouse soluble VEGFR-2/Flk-1 (GMEASLGDRIAMP).
Specificity	This antibody detects endogenous sVEGFR-2/Flk-1.
Formulation	PBS, pH 7.2 State: Purified State: Lyophilized purified IgG fraction
Reconstitution Method	Centrifuge vial prior to opening. Restore in sterile water to a concentration of 0.1-1.0 mg/ml.
Purification	Protein A Chromatography
Conjugation	Unconjugated
Storage Condition	Prior to reconstitution store at 2-8°C. Following reconstitution store undiluted at 2-8°C for one month  or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing.
Database Link	UniProt ID P35918
Background	Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.  Recombinant mouse esFlk-1 generated by alternative splicing consists of the first 6 Ig-like loops followed by the unique C-terminal end: GMEASLGDRIAMP.
Synonyms	VEGFR2, FLK1, KDR, VEGF Receptor 2
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.